FrancophonIA/ELRC3.0 huggingface dataset:
English: Cattle Sheep Trout Eel
Estonian: Ravimsööda eelsegu Forell
English: Poultry
Estonian: Kanad
English: FLUMAX 50% Flumequine
Estonian: FLUMAX 50% Flumekiin
English: Subcutaneous, Intravenous, intramuscular
Estonian: Subkutaanne, intravenoosne, intramuskulaarne
English: Ursofloxacin 10% Enrofloxacin 100 mg/ml
Estonian: Ursofloxacin 10% Enrofloksatsiin 100 mg/ml
English: Calves
Estonian: Lambad
English: Intramuscular, subcutaneous, intravenous
Estonian: Intramuskulaarne , subkutaanne, intravenoosne
English: Enroxil 5% injection Enrofloxacin 50 mg/ml
Estonian: Enroxil 5 % injection Enrofloksatsiin 50 mg/ml
English: Enroxil 5 % injection Enrofloxacin 50 mg/ml
Estonian: Enroxil 5% injection Enrofloksatsiin 50 mg/ml
English: Enrofloxacin 15 mg/tablet
Estonian: Enrofloksatsiin 15 mg/tablett
English: Intramuscular, intravenous, subcutaneous
Estonian: Intramuskulaarne , intravenoosne, subkutaanne
English: Poulrty
Estonian: Kitsed
English: Cattle Buffalos Calves Foals Lambs Kids Pigs Piglets Rabbits Fowl
Estonian: Veised Pühvlid Vasikad Varsad Lambatalled Kitsetalled Sead
English: Enrofloxacin 100 mg/g
Estonian: Enrofloksatsiin 100 mg/g
English: MARBOCYL 2% Marbofloxacin 20 mg/ml
Estonian: MARBOCYL 2% Marbofloksatsiin 20 mg/ml
English: Hungary Laboratorios Hipra, S.A. Avda.
Estonian: Hispaania Laboratorios Hipra, S.A. Avda.
English: Syvaquinol 10% Enrofloxacin 100 mg/ml
Estonian: Syvaquinol 10% Enrofloksatsiin 100 mg/ml
English: Cattle (neonatal calves)
Estonian: Veised (mittelakteeriva d lehmad)
English: Enrofloxarom 5% Enrofloxacin 50 mg/ml
Estonian: Enrofloxarom 5% Enrofloksatsiin 50 mg/ml
English: Poultry (chickens and turkeys)
Estonian: Kodulinnud (kanad ja kalkunid)
English: Flumequine Amoxicillin trihydrate
Estonian: Flumekiin Amoksitsilliintrih üdraat
English: Enrofloxacin 250 mg
Estonian: Enrofloksatsiin 250 mg
English: Special warning(s) “Official and local antimicrobial policies should be taken into account when the product is used.” “Whenever possible, quinolones should only be used based on susceptibility testing.” “Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the quinolones and may decrease the effectiveness of treatment with other (fluoro)quinolones due to the potential for cross resistance.”
Estonian: Erihoiatused “Ravimi kasutamisel tuleb arvestada ametlikku ja piirkondlikku antimikroobsete ühendite kasutamise poliitikat.” “Kinoloonide kasutamine peab igal võimalikul juhul tuginema üksnes tundlikkuse kindlaksmääramisele.” “Ravimi omaduste kokkuvõttes esitatud juhistest kõrvalekaldumine ravimi kasutamisel võib suurendada kinoloonide suhtes resistentsete bakterite esinemissagedust ja võib võimaliku ristresistentsuse tõttu vähendada ravi tõhusust teiste (fluoro)kinoloonidega.”
English: Enroxil 10 % injection Enrofloxacin 100 mg/ml
Estonian: Enroxil 10% injection Enrofloksatsiin 100 mg/ml
English: Enroxil 10% injection Enrofloxacin 100 mg/ml
Estonian: Enroxil 10 % injection Enrofloksatsiin 100 mg/ml
English: Cattle Pigs Poultry
Estonian: Veised Sead Kanad
English: Marbofloxacin 100 mg/ml
Estonian: Marbofloksatsiin 100 mg/ml
English: Enrofloxacin 10 g/100ml
Estonian: Enrofloksatsiin 10 g/100ml
English: Belgium Bayer N.V. Louizalaan 143
Estonian: Slovakkia Bayer s.r.o Litvínovská 609/3
English: Medicated premix Pigs Poultry
Estonian: Ravimsööda eelsegu Sead Kanad
English: Enrofloxacin 10 g/100 ml
Estonian: Enrofloksatsiin 10 g/100 ml
English: Poultry Cattle Rabbits
Estonian: Kodulinnud Veised Küülikud
English: Germany Krka, d. d., Novo mesto Šmarješka cesta 6
Estonian: Saksamaa Krka, d. d., Novo mesto Šmarješka cesta 6
English: MARBOCYL S 10% Marbofloxacin 100 mg/ml
Estonian: MARBOCYL S 10% Marbofloksatsiin 100 mg/ml
English: Cattle Goats Rabbits Sheep Fish Pigs Poultry
Estonian: Veised Kitsed Küülikud Lambad Kalad
English: Chickens Calves Pigs
Estonian: Kanad Vasikad Sead
English: Poultry Pigs Cattle
Estonian: Kanad Sead Tuvid
English: Romania Krka, d. d., Novo mesto Šmarješka cesta 6
Estonian: Rumeenia Krka, d. d., Novo mesto Šmarješka cesta 6
English: Poultry (excluding laying)
Estonian: Kodulinnud (väljaarvatud munejad)
English: Enrofloxacina 10% Enrofloxacin 100 mg/ml
Estonian: Enrofloxacina 10% Enrofloksatsiin 100 mg/ml
English: Enrobioflox 10% Enrofloxacin 100 mg/ml
Estonian: Enrobioflox 10% Enrofloksatsiin 100 mg/ml
English: Laboratorios Syva, S.A. Parroco Pablo Diez, 49-57 24010 Trobajo Del Camino SPAIN
Estonian: Hispaania Laboratorios Syva, S.A. Parroco Pablo Diez, 49-57
English: Enrofloxacin 50 mg/g
Estonian: Enrofloksatsiin 50 mg/g
English: Cattle Chickens Turkeys
Estonian: Gastroenteraallahus Kanad Kalkunid
English: Lithuania Vétoquinol S. A. Magny Vernois
Estonian: Prantsusmaa Vétoquinol S. A. Magny Vernois
English: Germany Krka, d.d., Novo mesto Šmarješka cesta 6
Estonian: Saksamaa Krka, d.d., Novo mesto Šmarješka cesta 6
English: Cattle Goats Horses Sheep Pigs Poultry
Estonian: Kassid Koerad Veised Lambad Kitsed Sead
English: Enrofloxacin 50 mg/tablet
Estonian: Enrofloksatsiin 50 mg/tablett
English: Enrofloxacin 100 mg
Estonian: Enrofloksatsiin 100 mg
English: Fenoflox 10 % Enrofloxacin 100 mg/ml
Estonian: Fenoflox 10% Enrofloksatsiin 100 mg/ml
English: Fenoflox 10% Enrofloxacin 100 mg/ml
Estonian: Fenoflox 10 % Enrofloksatsiin 100 mg/ml
English: Flumequine 50% Flumequine
Estonian: Flumequine 50% Flumekiin
English: DENMARK
Estonian: NETHERLAND
English: Enrofloxacin 10 % Enrofloxacin 100 mg/ml
Estonian: Enrofloxacin 10 % Enrofloksatsiin 100 mg/ml
English: Marbofloxacin 10%
Estonian: Marbofloksatsiin 10%
English: Germany Krka, d.d, Novo mesto Šmarješka cesta 6
Estonian: Saksamaa Krka, d.d, Novo mesto Šmarješka cesta 6
English: Foals
Estonian: Veised
English: Rabbits Poultry
Estonian: Põrsad Küülikud Kanad
English: Pigeons
Estonian: Kalkunid
English: Enrofloxacin 25 mg
Estonian: Enrofloksatsiin 25 mg
English: Cattle Sheep Goats Pigs
Estonian: Veised Lambad Kitsed Sead
English: Poultry Pigeons Cats Dogs Cattle Pigs
Estonian: Kassid Veised Koerad Sead
English: Lithuania Krka, d. d., Novo mesto Šmarješka cesta 6
Estonian: Slovakkia Krka, d. d., Novo mesto Šmarješka cesta 6
English: Enrofloxacin 5 mg
Estonian: Enrofloksatsiin 5 mg
English: Denmark Krka, d. d., Novo mesto Šmarješka cesta 6
Estonian: Madalmaad Krka, d. d., Novo mesto Šmarješka cesta 6
English: Cattle Sheep Goats Pigs Poultry Rabbit Fish
Estonian: Veised Lambad Kanad Sead Mink Nutria Küülikud
English: Marbocyl 10% Marbofloxacin 100 mg/ml
Estonian: Marbocyl 10% Marbofloksatsiin 100 mg/ml
English: MARBOCYL 10% Marbofloxacin 100 mg/ml
Estonian: MARBOCYL 10% Marbofloksatsiin 100 mg/ml
English: Chickens (excluding laying hens) Turkey
Estonian: Kanad (väljaarvatud munevad kanad) Kalkunid
English: Vetoflok 10% Enrofloxacin 100 mg/ml
Estonian: Vetoflok 10% Enrofloksatsiin 100 mg/ml
English: Pigs Lambs
Estonian: Lambad Kanad
English: Broilers Turkeys Rabbits
Estonian: Broilerid Kalkunid Küülikud
English: Enrofloxarom 10% Enrofloxacin 100 mg/ml
Estonian: Enrofloxarom 10% Enrofloksatsiin 100 mg/ml
English: Enrofloxacin 150 mg
Estonian: Enrofloksatsiin 150 mg
English: FLUMIQUIL 50% Flumequine
Estonian: Flumiquil 50 % Flumekiin
English: Flumiquil 50 % Flumequine
Estonian: FLUMIQUIL 50% Flumekiin
English: Cattle Pigs
Estonian: Kodulinnud Sead
English: Enrofloxacin 500 mg
Estonian: Enrofloksatsiin 500 mg
English: Broilers Turkeys
Estonian: Broilerid Kalkunid
English: Enrofloxacin 50 mg/ml
Estonian: Enrofloksatsiin 50 mg/ml
English: Intraruminal device Cattle
Estonian: Süstesuspensioon Veised Lambad
English: Trout
Estonian: Tuvid
English: Poultry Bovine Pigs Pigeons
Estonian: Veised Sead Kanad Broilerid
English: Calves Lambs Poultry
Estonian: Kanad Broilerid Kalkunid
English: Cattle Pigs Poultry Rabbits
Estonian: Sead Kanad Kalkunid
English: Enrodem 10% Enrofloxacin 100 mg/ml
Estonian: Enrodem 10% Enrofloksatsiin 100 mg/ml
English: Medicated premix Pigs Chickens
Estonian: Ravimsööda eelsegu Broilerid Sead
English: Enrovet 10% Enrofloxacin 100 mg/ml
Estonian: Enrovet 10% Enrofloksatsiin 100 mg/ml
English: Enrostar 10% Enrofloxacin 100 mg/ml
Estonian: Enrostar 10% Enrofloksatsiin 100 mg/ml
English: What is Advexin?
Estonian: Mis on Advexin?
English: The application was at day 179 when the company withdrew.
Estonian: Taotluse menetlemine oli kestnud 179 päeva, kui ettevõte võttis taotluse tagasi.
English: International non-proprietary name (INN): contusugene ladenovec
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): kontusugeenladenovek
English: Ref. EMEA/690893/2008
Estonian: London, 22. jaanuar 2009 Viide: EMEA/86054/2009
English: The Committee also had concerns over what happens to the medicine in the body, how it should be given and how safe it is.
Estonian: Komiteele valmistas muret ka see, et ei ole teada, mis organismis ravimiga toimub, kuidas seda peaks annustama ja kui ohutu on ravim.
English: Li-Fraumeni cancer can occur in many areas of the body but usually affects the breast, brain, bone or soft tissue (tissue that connects, surrounds and supports other structures in the body).
Estonian: Li-Fraumeni vähk võib esineda organismi mitmesugustes piirkondades, kuid enamasti tekib vähk rinnas, ajus, luudes või pehmekudedes (koed, mis ühendavad, ümbritsevad ja toetavad organismi teisi struktuure).
English: People who have this mutation are more likely to develop cancer.
Estonian: Selle mutatsiooniga inimestel on vähi teke tõenäosem.
English: This is a type of virus that has been altered genetically so that it can carry a gene into the cells of the body.
Estonian: See on teatud liiki viirus, mida on geneetiliselt muudetud nii, et see saaks viia geeni organismi rakkudesse.
English: Advexin was expected to cure or slow down the disease by restoring the normal protective function of the cells.
Estonian: Advexin pidi haigust ravima või aeglustama, taastades rakkude tavapärase kaitsefunktsiooni.
English: Advexin was designated as an orphan medicinal product on 23 October 2006.
Estonian: Advexin nimetati harvikravimiks 23. oktoobril 2006.
English: On 17 December 2008, Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Advexin for the treatment of Li-Fraumeni cancer.
Estonian: 17. detsembril 2008 teatas ettevõte Gendux Molecular Limited ametlikult inimravimite komiteele, et soovib tagasi võtta Li-Fraumeni vähi raviks ette nähtud ravimi Advexini müügiloa taotluse.
English: In addition, the company had not supplied enough evidence to demonstrate that Advexin could be made in a reliable manner, or that it would not be harmful to the environment or to people in close contact with the patient.
Estonian: Ettevõte ei olnud esitanud ka piisavalt tõendeid, mis oleks näidanud, et Advexinit saab usaldusväärsel viisil valmistada, ja et ravim ei ole kahjulik keskkonnale ega patsiendiga vahetult kokku puutuvatele isikutele.
English: The effectiveness of the medicine was assessed by using scans to look at how the tumours responded to treatment.
Estonian: Ravimi efektiivsust hinnati skaneerimisega, mis näitas kasvajate allumist ravile.
English: Advexin was expected to be used to treat Li-Fraumeni cancer in patients from the age of 18 years.
Estonian: Advexinit kavandati kasutada Li-Fraumeni vähi raviks üle 18-aastastel patsientidel.
English: The company also presented the results of a number of small studies looking at the effects of a range of doses of Advexin on different types of cancer.
Estonian: Ettevõte esitas ka teaduskirjandusest mitme väiksema uuringu tulemused, mis käsitlesid Advexini eri annuste mõju mitmesugustele vähiliikidele.
English: Questions and answers on the withdrawal of the marketing application for Advexin
Estonian: Teave müügiloa taotluse tagasivõtmise kohta Advexin
English: The patient received 12 Advexin injections into some of the tumours over a five-month period.
Estonian: Patsiendi kasvajatesse tehti viie kuu kestel 12 Advexini süsti.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Advexin could not have been approved for the treatment of Li-Fraumeni cancer.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi inimravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Advexini kasutamist Li-Fraumeni vähi raviks ei ole võimalik heaks kiita.
English: The virus in Advexin is an ‘adenovirus' that has been engineered so that it cannot make copies of itself and therefore does not cause infections in humans.
Estonian: Advexinis olev viirus on adenoviirus, mida on muudetud nii, et see ei suuda iseseisvalt paljuneda ega põhjusta seetõttu inimestel nakkust.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin?
Estonian: Millised on taotluse tagasivõtmise tagajärjed praegu Advexini kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: Advexin is a suspension for injection that contains contusugene ladenovec, a genetically modified virus which carries the p53 gene.
Estonian: Advexin on süstesuspensioon, mis sisaldab kontusugeenladenovekit, geneetiliselt muundatud viirust, mis kannab p53-geeni.
English: Li-Fraumeni cancer is a type of cancer that occurs in patients with Li-Fraumeni syndrome, a condition where a gene called p53 is defective because of a mutation.
Estonian: Li-Fraumeni vähk esineb patsientidel, kellel on Li-Fraumeni sündroom - haigusseisund, mille korral p53-geen on mutatsiooni tõttu defektne.
English: Because cancer cells contain damaged DNA, the p53 protein either helps to repair the DNA or causes the cells to die.
Estonian: Et vähirakud sisaldavad kahjustatud DNA-d, siis p53-valk kas aitab DNA-d parandada või hävitab rakud.
English: The effects of Advexin were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Advexini toimet muude katsetega.
English: The gene carried by the virus in Advexin is the normal (non-defective) p53 gene.
Estonian: Advexini viiruse kantav geen on normaalne (defektita) p53-geen.
English: The CHMP was concerned that there was not enough evidence to show that the injection of Advexin into Li-Fraumeni tumours led to benefits for patients.
Estonian: Inimravimite komitee ettevaatlikkust põhjustas piisavate tõendite puudumine selle kohta, et Advexini süstimine Li-Fraumeni kasvajatesse on patsiendile kasulik.
English: Advexin was expected to be injected directly into the tumours, thus allowing the cancer cells to produce normal p53 protein again.
Estonian: Advexinit kavatseti süstida otse kasvajasse, et vähirakkudes tekiks taas normaalne p53-valk.
English: In Li-Fraumeni cancer, where the p53 gene is defective, the p53 protein does not work properly and the cancer cells can continue to grow and divide.
Estonian: Li-Fraumeni vähis, mille p53-geen on defektne, ei toimi p53-valk normaalsel viisil ning vähirakud saavad kasvada ja jaguneda.
English: What was Advexin expected to be used for?
Estonian: Milleks kavatseti Advexinit kasutada?
English: The company did not inform the CHMP whether there were any consequences of the withdrawal for patients in clinical trials or compassionate use programmes with Advexin.
Estonian: Ettevõte ei teatanud inimravimite komiteele, kas müügiloa taotluse tagasivõtmine avaldab mõju praegu Advexini kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele.
English: The company presented information from a study on one patient with Li-Fraumeni cancer in the lower abdomen, the bones and the brain.
Estonian: Patsiendil oli Li-Fraumeni vähk alakõhus, luudes ja ajus.
English: How is Advexin expected to work?
Estonian: Milline on Advexini eeldatav toime?
English: The active substance in Advexin, contusugene ladenovec, is a ‘viral vector'.
Estonian: Advexini toimeaine kontusugeenladenovek on viirusvektor.
English: The p53 protein, which is produced from the non-defective p53 gene present in the human body, normally contributes to the repair of damaged DNA and causes cell death when the DNA cannot be repaired.
Estonian: See valk, mida tekitab inimorganismis olev defektita p53-geen, tavaliselt aitab kahjustatud DNA-d parandada, ning kui parandada ei saa, hävitab raku.
English: What measures are being taken to ensure the safe and effective use of Kymriah?
Estonian: Mis meetmed võetakse, et tagada Kymriahi ohutu ja efektiivne kasutamine?
English: Further information on Kymriah can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Kymriahi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Kymriah and what is it used for?
Estonian: Mis on Kymriah ja milleks seda kasutatakse?
English: The European Medicines Agency therefore decided that Kymriah's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Kymriahi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: These results were comparable to those from studies of patients receiving standard cancer treatments.
Estonian: Need tulemused olid võrreldavad tulemustega uuringust, milles osalesid standardset vähiravi saanud patsiendid.
English: Patients should be closely monitored for 10 days after treatment for side effects and are advised to stay close to a specialist hospital for at least 4 weeks after treatment.
Estonian: Pärast ravi tuleb patsiente 10 päeva hoolikalt jälgida kõrvalnähtude suhtes ning neil soovitatakse jääda pärast ravi vähemalt 4 nädalaks erihaigla lähedusse.
English: As for all medicines, data on the use of Kymriah are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Kymriahi kasutamise kohta pidevat järelevalvet.
English: This was better than results seen with the cancer medicines clofarabine, blinatumomab or a combination of clofarabine, cyclophosphamide and etoposide.
Estonian: See tulemus oli parem kui tulemused, mis saadi vähiravimitega klofarabiin ja blinatumomaab või klofarabiini, tsüklofosfamiidi ja etoposiidi kombinatsiooniga.
English: Serious side effects occur in most patients.
Estonian: Raskeid kõrvalnähte esineb enamikul patsientidel.
English: The company must carry out several studies to obtain more information on Kymriah including its safety and effectiveness in the long term and in B-cell ALL patients under 3 years of age.
Estonian: Turustaja peab korraldama mitu uuringut, et saada Kymriahi kohta rohkem teavet, sealhulgas selle ohutuse ja efektiivsuse kohta pikas perspektiivis ning alla 3-aastastel B-rakulise ägeda lümfoblastleukeemiaga patsientidel.
English: Kymriah (tisagenlecleucel)
Estonian: Kymriah (tisageenlekleutseel)
English: What are the risks associated with Kymriah?
Estonian: Mis riskid Kymriahiga kaasnevad?
English: Kymriah is a medicine for treating two types of blood cancer:
Estonian: Kymriah on ravim, mida kasutatakse kaht liiki verevähi raviks:
English: How is Kymriah used?
Estonian: Kuidas Kymriahi kasutatakse?
English: However these are manageable if the appropriate measures are in place (see below).
Estonian: Asjakohaste meetmetega (vt allpool) on need kõrvalnähud siiski hallatavad.
English: For more information about using Kymriah, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Kymriahi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Twelve months after treatment, the likelihood of survival was 70%.
Estonian: 12 kuud pärast ravi oli elumuse tõenäosus 70%.
English: Twelve months after treatment, the likelihood of survival was 40%.
Estonian: 12 kuud pärast ravi oli elumuse tõenäosus 40%.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kymriah have also been included in the summary of product characteristics and the package leaflet.
Estonian: Kymriahi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: In patients with DLBCL treated with Kymriah, the results were similar to other treatments but ongoing study data indicate that the effects last longer.
Estonian: Difuusse B-suurrakklümfoomiga patsientidel olid Kymriah-ravi tulemused sarnased muude ravitulemustega, kuid toimuva uuringu andmed tõendavad, et Kymriahi toime kestab kauem.
English: The most common serious side effects are cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and decreases in platelets (components that help the blood to clot), haemoglobin (the protein found in red blood cells that carries oxygen around the body) or white blood cells including neutrophils and lymphocytes.
Estonian: Kõige sagedamad rasked kõrvalnähud on tsütokiinide vabanemise sündroom (potentsiaalselt eluohtlik seisund, mis võib põhjustada palavikku, oksendamist, hingeldust, valu ja madalat vererõhku) ning trombotsüütide (vere hüübimist soodustavad vererakud), hemoglobiini (organismis hapnikku transportiv erütrotsüütide valk) või leukotsüütide, sealhulgas neutrofiilide ja lümfotsüütide sisalduse vähenemist.
English: Side effects reported with Kymriah are carefully evaluated and any necessary action taken to protect patients.
Estonian: Kymriahi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Around 24% of patients had a complete response and 34% had at least a partial response after at least 3 months.
Estonian: Pärast vähemalt 3 kuu möödumist oli täieliku ravivastusega patsiente ligikaudu 24% ja vähemalt osalise ravivastusega patsiente 34%.
English: CAR can attach to another protein on the surface of cancer cells called CD19.
Estonian: CAR seondub vähirakkude pinnal teise valguga (CD19).
English: The company must provide educational materials for healthcare professionals and patients about possible side effects, especially cytokine release syndrome.
Estonian: Turustaja peab tervishoiutöötajatele ja patsientidele tagama teabematerjali võimalike kõrvalnähtude, eelkõige tsütokiinide vabanemise sündroomi kohta.
English: The company that markets Kymriah must ensure that hospitals where Kymriah is given have appropriate expertise, facilities and training.
Estonian: Kymriahi turustaja peab tagama, et haiglates, kus Kymriahi patsientidele manustatakse, on olemas asjakohased eriteadmised, ruumid ja koolitused.
English: B-cell ALL
Estonian: Difuusne B-suurrakklümfoom
English: Kymriah contains the active substance tisagenlecleucel (consisting of genetically modified white blood cells).
Estonian: Kymriah sisaldab toimeainena tisageenlekleutseeli (mis koosneb geneetiliselt modifitseeritud leukotsüütidest).
English: The majority of patients who responded to Kymriah continued to have a response after 19 months.
Estonian: Enamikul patsientidest, kellel tekkis Kymriahiga ravivastus, säilis see ka pärast 19 kuu möödumist.
English: Serious infections occur in around 3 in 10 DLBCL patients.
Estonian: Difuusse B-suurrakklümfoomiga patsientidest esineb raskeid infektsioone ligikaudu 3 patsiendil 10st.
English: For the full list of side effects and restrictions with Kymriah, see the package leaflet.
Estonian: Kymriahi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Serious side effects, occur in most patients, and can include cytokine release syndrome.
Estonian: Enamikul patsientidest esineb raskeid kõrvalnähte, sealhulgas võib tekkida tsütokiinide vabanemise sündroom.